IRD

#3325
Opus Genetics, Inc. - Common Stock
3.5 8 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.56
3.65
Jahresspanne
2.82
5.81
Tagesänderung
-2.98%
Monatliche Änderung
-3.76%
6 month change
-12.25%
Jahresänderung
-3.76%
Vorheriger Schlusskurs
3.6 9
Open
3.6 3
Tief
3.5 6
Hoch
3.6 5
Volumen
89
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 11 November 2020

Full document

Business Context and Reporting Period

This Form 8-K is filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on November 17, 2020, reporting events that occurred on November 11, 2020. The filing addresses Item 5.02 regarding the appointment of a new senior officer and the associated compensatory arrangements.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details.

Material Changes and Executive Appointment

On November 11, 2020, Ocuphire Pharma, Inc. appointed Amy Rabourn as Vice President of Finance and Principal Accounting Officer. Ms. Rabourn brings over 18 years of finance and accounting experience, including public company experience in the life sciences sector. Her background includes serving as Director of Finance at Gemphire Therapeutics, Inc., where she supported the company's IPO and managed financial operations post-merger with NeuroBo Pharmaceuticals, Inc.

Compensatory Arrangements and Outlook

The Company entered into a three-year employment agreement with Ms. Rabourn, effective November 11, 2020, with automatic one-year renewal terms. Key compensation components include:

  • Base Salary: At least $240,000 annually, subject to annual review.
  • Signing Bonus: $10,000.
  • Annual Cash Bonus: Up to 30% of the annual base salary.
  • Equity: Participation in equity-based long-term incentive plans and a grant of options to purchase common stock.
  • Benefits: Participation in standard welfare benefit plans available to senior executives.

Investor Verification Checklist

  • Verify the exact number of stock options granted to Ms. Rabourn, as the filing mentions the grant but does not specify the quantity or exercise price.
  • Confirm the Company's current cash position to assess the immediate impact of the $10,000 signing bonus and future salary obligations.
  • Review the Company's most recent 10-Q or 10-K for updated financial performance metrics, as this 8-K contains no operational or financial data.